|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
SB11-G31-AMD |
Degeneration der Makula und des hinteren Poles
[H35.3]
|
A Phase III Randomized, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucentis® in Subjects with Neovascular Age-Related Macular Degeneration
|
 |
 |
|
SCH 56592 Protokoll P05520 |
Akute myeloblastische Leukämie [AML]
[C92.0-]
|
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections
|
|
|
|
|
Schnarchgeräusche |
Schlafapnoe
[G47.3]
|
Keine Angabe
|
 |
|
|
|
SCY-078-301 AM1 FURI |
|
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
|
|
|
|
|
SEAVUE |
Reizdarmsyndrom mit Diarrhoe
[K58.0]
|
A phase 3b, multicenter, randomized, blinded, active-controlled study to compare the efficacy and safety of Ustekinumab to that of Adalimumab in the treatment of biologic naive subjects with moderately-to-severely active Crohn's Disease
|
|
|
|
|
Selene |
Follikuläres Lymphom o.n.A.
[9690/3]
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine
Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Either Bendamustine and
Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and
Pred
|
|
|
|
|
sensitize |
Bösartiges Melanom der Haut, nicht näher bezeichnet
[C43.9]
|
An open-label Phase Ib/ II, multi-center study of 4SC-202 in Combination with Pembrolizumab in Patients with Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma primary refractory/non-responding to prior Anti-PD-1 Therapy – The SENSITIZE Study
|
|
|
|
|
SEQTOR |
Bösartige Neubildung ohne Angabe der Lokalisation
[C80.-]
|
Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR study)
|
|
|
|
|
SEROGLI |
Gehirn, nicht näher bezeichnet
[C71.9]
|
Detektion serologischer Genexpressionsmuster (mRNA, miRNA) zur Bestimmung der therapieassoziierten Tumorlast bei Glioblastom WHO °IV
|
|
|
|
|
SGI-110-04 |
Akute myeloblastische Leukämie [AML]
[C92.0-]
|
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
|
 |
|
|
|
SGI-110-06 - ASTRAL-2 |
|
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus
Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
|
|
|
|
|
SGNLVA-002 |
Brustdrüse, nicht näher bezeichnet
[C50.9]
|
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
|
|
|
|
|
SHINE (PCI-32765 MCL3002) |
Sonstige nicht follikuläre Lymphome
[C83.8]
|
Protocol PCI-32765MCL3002; Phase 3
|
|
|
|
|
Simulationsstudie |
Arteriographie der intrakraniellen Gefäße
[-]
|
Implementierung und Validierung eines
Simulationstrainings in der neuroradiologischen
Angiographie
|
|
|
|
|
SINTRA-REV |
Myelodysplastisches Syndrom mit isolierter del(5q)-Chromosomenanomalie
[D46.6]
|
Multicenter, randomized, double-blind, phase III study of Revlimid (Lenalidomide) versus Placebo in patients wih low risk myelodysplastic syndrome (low and intermediate-1 IPSS) with alteration in 5q and anemia without the need of transfusion. (MDS)
|
|
|
|
|
SIOP CNS GCT II |
Gehirn, nicht näher bezeichnet
[C71.9]
|
Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours
|
|
|
|
|
SIRFLOX |
Bösartige Neubildung am Rektosigmoid, Übergang
[C19]
|
Randomised comparative study of FOLFOX6m plus SIR-Spheres? microspheres versus FOLFOX6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma
|
|
|
|
|
SIRTACE |
Leberzellkarzinom
[C22.0]
|
Study of Radioembolisation(RE) with SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation(TACE) in Patients With Unresectable Hepatocellular Carcinoma
|
|
|
|
|
SM101-201-itp-09 |
Idiopathische thrombozytopenische Purpura
[D69.3]
|
A Randomised, Multi-Centre, Double-Blind, Placebo-Controlled, Single/MultipleDose Escalation Phase Ib/IIa Clinical Trial to Investigate the Safety and Efficacy ofRecombinant Human Soluble Fc-gamma Receptor IIb (SM101) for IntravenousApplication in the Treatment of Patients with Chronic Adult IdiopathicThrombocytopenic Purpura (ITP)
|
 |
|
|
|
SMART-MI |
Sonstige akute Komplikationen nach akutem Myokardinfarkt
[I23.8]
|
Implantable cardiac monitorS in high-risk post-infarction patients with cardiac autonoMic dysfunction And modeRaTely reduced left ventricular ejection fraction
|
|
|
|
|
Soccer |
Bösartige Neubildungen der Lippe, der Mundhöhle und des Pharynx
[C00-C14]
Bösartige Neubildung des Larynx
[C32.-]
|
Untersuchung zur Systemkontrolle bei Patienten mit rezidiviertem und/ oder metastasiertem SCCHN unter Erstlinientherapie mit Erbitux® -SOCCER-
|
|
|
|
|
SOM230C2303 |
GEP-NET
[C15-C26, D13]
|
Eine multizentrische, randomisierte, verblindete Studie zur Beurteilung der Wirksamkeit und Sicherheit von Pasireotid LAR vs. Octreotid LAR bei Patienten mit metastasiertem Karzinoid, deren krankheitsbedingte Symptome mit Somatostatin-Analoga unzureichend gelindert werden
|
|
|
|
|
SomVeDi - PCSII-2 |
Somatisierungsstörung
[F45.0]
|
Tailored care for somatoform vertigo/dizziness - From diagnostics to therapy
|
|
|
|
|
SONNET |
Bösartige Neubildung sonstiger endokriner Drüsen und verwandter Strukturen
[C75.-]
|
Phase II, multicentre, open label study to evaluate the efficacy of the
combination of Lanreotide Autogel 120 mg and Temozolomide in patients
with progressive gastro-entero-pancreatic neuroendocrine tumours (GEPNET)
G1/G2 - A Pilot-Study
SONNET – Somatuline in NET with Temozolomide
|
|
|
|
|
SORAMIC |
Leberzellkarzinom
[C22.0]
|
HCC, Hepatozelluläres Karzinom, Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma, SORAMIC
|
|
|
